Coherus BioSciences (CHRS) announced a clinical collaboration with STORM Therapeutics (STORM) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI in a Phase 1b/2 study for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma and endometrial cancer. Coherus will provide LOQTORZI to STORM, which will be the sponsor of the Phase 1b/2 combination trial.
The phase 1b study will evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI to determine the safety and efficacy of the combination. The phase 2 portion of the study will evaluate expansion cohorts in NSCLC, HNSCC, endometrial cancer and melanoma, in up to 188 patients in the United States.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.